Cargando…

Hepatitis B Prophylaxis after Liver Transplantation in Korea: Analysis of the KOTRY Database

BACKGROUND: Prophylaxis for hepatitis B virus (HBV) recurrence is essential after liver transplantation (LT) in HBV-associated recipients. We conducted real-world analysis of HBV prophylaxis after LT in the Korean population. METHODS: Korean Organ Transplantation Registry (KOTRY) database and additi...

Descripción completa

Detalles Bibliográficos
Autores principales: Park, Gil-Chun, Hwang, Shin, Kim, Myoung-Soo, Jung, Dong-Hwan, Song, Gi-Won, Lee, Kwang-Woong, Kim, Jong Man, Lee, Jae Geun, Ryu, Je Ho, Choi, Dong Lak, Wang, Hee-Jung, Kim, Bong-Wan, Kim, Dong-Sik, Nah, Yang Won, You, Young Kyoung, Kang, Koo Jeong, Yu, Hee Chul, Park, Yo-Han, Lee, Kyung Jin, Kim, Yun Kyu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025905/
https://www.ncbi.nlm.nih.gov/pubmed/32056398
http://dx.doi.org/10.3346/jkms.2020.35.e36
_version_ 1783498582152708096
author Park, Gil-Chun
Hwang, Shin
Kim, Myoung-Soo
Jung, Dong-Hwan
Song, Gi-Won
Lee, Kwang-Woong
Kim, Jong Man
Lee, Jae Geun
Ryu, Je Ho
Choi, Dong Lak
Wang, Hee-Jung
Kim, Bong-Wan
Kim, Dong-Sik
Nah, Yang Won
You, Young Kyoung
Kang, Koo Jeong
Yu, Hee Chul
Park, Yo-Han
Lee, Kyung Jin
Kim, Yun Kyu
author_facet Park, Gil-Chun
Hwang, Shin
Kim, Myoung-Soo
Jung, Dong-Hwan
Song, Gi-Won
Lee, Kwang-Woong
Kim, Jong Man
Lee, Jae Geun
Ryu, Je Ho
Choi, Dong Lak
Wang, Hee-Jung
Kim, Bong-Wan
Kim, Dong-Sik
Nah, Yang Won
You, Young Kyoung
Kang, Koo Jeong
Yu, Hee Chul
Park, Yo-Han
Lee, Kyung Jin
Kim, Yun Kyu
author_sort Park, Gil-Chun
collection PubMed
description BACKGROUND: Prophylaxis for hepatitis B virus (HBV) recurrence is essential after liver transplantation (LT) in HBV-associated recipients. We conducted real-world analysis of HBV prophylaxis after LT in the Korean population. METHODS: Korean Organ Transplantation Registry (KOTRY) database and additionally collected data (n = 326) were analyzed with special reference to types of HBV prophylaxis. RESULTS: The study cohort comprised 267 cases of living-donor LT and 59 cases of deceased-donor LT. Hepatocellular carcinoma (HCC) was diagnosed in 232 (71.2%) of these subjects. Antiviral agents were used in 255 patients (78.2%) prior to LT. HBV DNA was undetectable in 69 cases (21.2%) and detectable over wide concentrations in the other 257 patients (78.8%) prior to LT. Polymerase chain reaction analysis of the store blood samples detected HBV DNA in all patients, with 159 patients (48.9%) showing concentrations > 100 IU/mL. Post-transplant HBV regimens during the first year included combination therapy in 196 (60.1%), hepatitis B immunoglobulin (HBIG) monotherapy in 121 (37.1%), and antiviral monotherapy in 9 (2.8%). In the second post-transplant year, these regimens had changed to combination therapy in 187 (57.4%), HBIG monotherapy in 112 (34.4%), and antiviral monotherapy in 27 (8.3%). Trough antibody to hepatitis B surface antigen titers > 500 IU/mL and >1,000 IU/mL were observed in 61.7% and 25.2%, respectively. The mean simulative half-life of HBIG was 21.6 ± 4.3 days with a median 17.7 days. Up to 2-year follow-up period, HCC recurrence and HBV recurrence developed in 18 (5.5%) and 6 (1.8%), respectively. HCC recurrence developed in 3 of 6 patients with HBV recurrence. CONCLUSION: Combination therapy is the mainstay of HBV prophylaxis protocols in a majority of Korean LT centers, but HBIG was often administered excessively. Individualized optimization of HBIG treatments using SHL is necessary to adjust the HBIG infusion interval.
format Online
Article
Text
id pubmed-7025905
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher The Korean Academy of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-70259052020-02-20 Hepatitis B Prophylaxis after Liver Transplantation in Korea: Analysis of the KOTRY Database Park, Gil-Chun Hwang, Shin Kim, Myoung-Soo Jung, Dong-Hwan Song, Gi-Won Lee, Kwang-Woong Kim, Jong Man Lee, Jae Geun Ryu, Je Ho Choi, Dong Lak Wang, Hee-Jung Kim, Bong-Wan Kim, Dong-Sik Nah, Yang Won You, Young Kyoung Kang, Koo Jeong Yu, Hee Chul Park, Yo-Han Lee, Kyung Jin Kim, Yun Kyu J Korean Med Sci Original Article BACKGROUND: Prophylaxis for hepatitis B virus (HBV) recurrence is essential after liver transplantation (LT) in HBV-associated recipients. We conducted real-world analysis of HBV prophylaxis after LT in the Korean population. METHODS: Korean Organ Transplantation Registry (KOTRY) database and additionally collected data (n = 326) were analyzed with special reference to types of HBV prophylaxis. RESULTS: The study cohort comprised 267 cases of living-donor LT and 59 cases of deceased-donor LT. Hepatocellular carcinoma (HCC) was diagnosed in 232 (71.2%) of these subjects. Antiviral agents were used in 255 patients (78.2%) prior to LT. HBV DNA was undetectable in 69 cases (21.2%) and detectable over wide concentrations in the other 257 patients (78.8%) prior to LT. Polymerase chain reaction analysis of the store blood samples detected HBV DNA in all patients, with 159 patients (48.9%) showing concentrations > 100 IU/mL. Post-transplant HBV regimens during the first year included combination therapy in 196 (60.1%), hepatitis B immunoglobulin (HBIG) monotherapy in 121 (37.1%), and antiviral monotherapy in 9 (2.8%). In the second post-transplant year, these regimens had changed to combination therapy in 187 (57.4%), HBIG monotherapy in 112 (34.4%), and antiviral monotherapy in 27 (8.3%). Trough antibody to hepatitis B surface antigen titers > 500 IU/mL and >1,000 IU/mL were observed in 61.7% and 25.2%, respectively. The mean simulative half-life of HBIG was 21.6 ± 4.3 days with a median 17.7 days. Up to 2-year follow-up period, HCC recurrence and HBV recurrence developed in 18 (5.5%) and 6 (1.8%), respectively. HCC recurrence developed in 3 of 6 patients with HBV recurrence. CONCLUSION: Combination therapy is the mainstay of HBV prophylaxis protocols in a majority of Korean LT centers, but HBIG was often administered excessively. Individualized optimization of HBIG treatments using SHL is necessary to adjust the HBIG infusion interval. The Korean Academy of Medical Sciences 2020-01-08 /pmc/articles/PMC7025905/ /pubmed/32056398 http://dx.doi.org/10.3346/jkms.2020.35.e36 Text en © 2020 The Korean Academy of Medical Sciences. https://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Park, Gil-Chun
Hwang, Shin
Kim, Myoung-Soo
Jung, Dong-Hwan
Song, Gi-Won
Lee, Kwang-Woong
Kim, Jong Man
Lee, Jae Geun
Ryu, Je Ho
Choi, Dong Lak
Wang, Hee-Jung
Kim, Bong-Wan
Kim, Dong-Sik
Nah, Yang Won
You, Young Kyoung
Kang, Koo Jeong
Yu, Hee Chul
Park, Yo-Han
Lee, Kyung Jin
Kim, Yun Kyu
Hepatitis B Prophylaxis after Liver Transplantation in Korea: Analysis of the KOTRY Database
title Hepatitis B Prophylaxis after Liver Transplantation in Korea: Analysis of the KOTRY Database
title_full Hepatitis B Prophylaxis after Liver Transplantation in Korea: Analysis of the KOTRY Database
title_fullStr Hepatitis B Prophylaxis after Liver Transplantation in Korea: Analysis of the KOTRY Database
title_full_unstemmed Hepatitis B Prophylaxis after Liver Transplantation in Korea: Analysis of the KOTRY Database
title_short Hepatitis B Prophylaxis after Liver Transplantation in Korea: Analysis of the KOTRY Database
title_sort hepatitis b prophylaxis after liver transplantation in korea: analysis of the kotry database
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7025905/
https://www.ncbi.nlm.nih.gov/pubmed/32056398
http://dx.doi.org/10.3346/jkms.2020.35.e36
work_keys_str_mv AT parkgilchun hepatitisbprophylaxisafterlivertransplantationinkoreaanalysisofthekotrydatabase
AT hwangshin hepatitisbprophylaxisafterlivertransplantationinkoreaanalysisofthekotrydatabase
AT kimmyoungsoo hepatitisbprophylaxisafterlivertransplantationinkoreaanalysisofthekotrydatabase
AT jungdonghwan hepatitisbprophylaxisafterlivertransplantationinkoreaanalysisofthekotrydatabase
AT songgiwon hepatitisbprophylaxisafterlivertransplantationinkoreaanalysisofthekotrydatabase
AT leekwangwoong hepatitisbprophylaxisafterlivertransplantationinkoreaanalysisofthekotrydatabase
AT kimjongman hepatitisbprophylaxisafterlivertransplantationinkoreaanalysisofthekotrydatabase
AT leejaegeun hepatitisbprophylaxisafterlivertransplantationinkoreaanalysisofthekotrydatabase
AT ryujeho hepatitisbprophylaxisafterlivertransplantationinkoreaanalysisofthekotrydatabase
AT choidonglak hepatitisbprophylaxisafterlivertransplantationinkoreaanalysisofthekotrydatabase
AT wangheejung hepatitisbprophylaxisafterlivertransplantationinkoreaanalysisofthekotrydatabase
AT kimbongwan hepatitisbprophylaxisafterlivertransplantationinkoreaanalysisofthekotrydatabase
AT kimdongsik hepatitisbprophylaxisafterlivertransplantationinkoreaanalysisofthekotrydatabase
AT nahyangwon hepatitisbprophylaxisafterlivertransplantationinkoreaanalysisofthekotrydatabase
AT youyoungkyoung hepatitisbprophylaxisafterlivertransplantationinkoreaanalysisofthekotrydatabase
AT kangkoojeong hepatitisbprophylaxisafterlivertransplantationinkoreaanalysisofthekotrydatabase
AT yuheechul hepatitisbprophylaxisafterlivertransplantationinkoreaanalysisofthekotrydatabase
AT parkyohan hepatitisbprophylaxisafterlivertransplantationinkoreaanalysisofthekotrydatabase
AT leekyungjin hepatitisbprophylaxisafterlivertransplantationinkoreaanalysisofthekotrydatabase
AT kimyunkyu hepatitisbprophylaxisafterlivertransplantationinkoreaanalysisofthekotrydatabase